| 23rd week of 2015 patent applcation highlights part 7 |
| Patent application number | Title | Published |
|---|
| 20150150783 | REGENERATION COMPOSITION AND METHOD FOR NATURAL HAIR RECOLORATION AND STIMULATION OF HAIR GROWTH BY PROCESSED MAKROOT FRUIT EXTRACT - The invention refers to a natural hair re-coloration and hair growth composition comprising boiled Makroot fruit ( | 2015-06-04 |
| 20150150784 | DERMATOLOGICAL COMPOSITION CONTAINING CULTURED THEOBROMA CACAO CELLS OR ITS EXTRACTS AND RELATED METHODS - A dermatological composition for inhibiting or treating inflammation and/or aging of skin includes a dermatologically compatible component and cultured cells derived from the | 2015-06-04 |
| 20150150785 | COSMETIC COMPOSITIONS COMPRISING MAGNETOSOMES AND USES THEREOF - The present invention relates to cosmetic and skin care compositions comprising magnetosomes. The invention also relates to methods for the treatment of diseases associated with increased proliferation or accumulation of differentiating keratinocytes. | 2015-06-04 |
| 20150150786 | FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES - An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release. | 2015-06-04 |
| 20150150787 | COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS - Pharmaceutical compositions, systems and methods suitable for respiratory delivery of a fixed combination of LAMA, LABA, and ICS active agents are described. The pharmaceutical compositions described herein may be formulated for respiratory delivery via a metered dose inhaler (MDI). Also described herein are MDI systems for delivery of a fixed combination of LAMA, LABA, and ICS active agents, as well as methods for preparing and using the compositions and systems described herein. | 2015-06-04 |
| 20150150788 | METHOD AND COMPOSITION FOR DELIVERING A COMPOUND THROUGH A BIOLOGICAL BARRIER - A method for delivering a compound through a biological barrier including applying a force to a plurality of microparticles on a surface of the barrier so that at least some of the microparticles penetrate the biological barrier to facilitate delivery of the compound therethrough. | 2015-06-04 |
| 20150150789 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR PREVENTING INFECTION IN SURGICAL INCISION SITES - An antimicrobial composition and methods of making the same are disclosed herein. In one aspect of the invention, an antimicrobial composition comprising one or more bioresorbable polymer drug particles and at least one polymer, the polymer drug particle including at least one bioresorbable polymer and at least one antimicrobial agent, wherein the composition is formulated for topical application to a surgical incision site in the subject. | 2015-06-04 |
| 20150150790 | TRANSDERMAL ENHANCER - The present invention is related to a composition for enhancing topical and transdermal absorption comprising an alkali material having a pH in the range of about 9.0 to 14.0 and a water-soluble substance in an amount of more than 0.5 wt % based on a total weight of the composition. The present invention is also related to a pharmaceutical composition comprising the composition, at least one therapeutically effective amount of a drug or an effective cosmetic ingredient, and a pharmaceutically acceptable carrier. The present invention is also related to a method for enhancing and delivering a drug through a body surface to minimize or eliminate the possibility of skin damage, irritation or sensitization while the above-described composition or the pharmaceutical composition is crossing patient's skin or mucosal tissue. | 2015-06-04 |
| 20150150791 | Risperidone or Paliperidone Implant Formulation - The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods. | 2015-06-04 |
| 20150150792 | PRODUCTS AND METHODS FOR REDUCING MALODOR FROM THE PUDENDUM - Products and methods are disclosed for reducing the production of unwanted odors from the pudendum. | 2015-06-04 |
| 20150150793 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2015-06-04 |
| 20150150794 | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS - Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject. | 2015-06-04 |
| 20150150795 | TIME-RELEASE AND MICRO-DOSE FORMULATIONS FOR TOPICAL APPLICATION OF ESTROGEN AND ESTROGEN ANALOGS OR OTHER ESTROGEN RECEPTOR MODULATORS IN THE TREATMENT OF DRY EYE SYNDROME, AND METHODS OF PREPARATION AND APPLICATION - A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients. | 2015-06-04 |
| 20150150796 | Cryopreserved Implantable Cell Culture Devices and Uses Thereof - The invention provides cryopreserved encapsulated cell therapy devices that are capable of delivering biologically active molecules as well as methods of using these devices. | 2015-06-04 |
| 20150150797 | PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT - An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof. | 2015-06-04 |
| 20150150798 | FAST DISSOLVING PHARMACEUTICAL COMPOSITION - The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan. | 2015-06-04 |
| 20150150799 | Delivery of Therapeutic Compounds to the Brain and Other Tissues - The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders. | 2015-06-04 |
| 20150150800 | MINERAL SUPPLEMENTATION OF BEVERAGES - The present invention is directed to metal supplementation of beverages. More particularly, it is directed to a metal containing complex coacervate core micelle comprising a negatively charged chelating agent, a low molecular weight natural food-grade polymeric cation, and water. It is also directed to a process to produce said metal containing complex coacervate core micelle, and to the use of said metal containing complex coacervate core micelle to supplement beverages with a source of highly bioavailable metal. It is also related to a beverage comprising said metal containing complex coacervate core micelle. | 2015-06-04 |
| 20150150801 | DOUBLE-LAYERED LIPOSOME COMPRISING INNER LIPOSOME COMPRISING HYDROPHOBIC ACTIVE INGREDIENT AND USE OF THE DOUBLE-LAYERED LIPOSOME - A double-layered liposome comprising a first liposome comprising a hydrophobic active ingredient and a first lipid bilayer containing the hydrophobic active ingredient; and a second liposome comprising a second lipid bilayer having an inner space in which the first liposome is located; and a method of using the double-layered liposome. | 2015-06-04 |
| 20150150802 | DRY POWDER INHALER COMPOSITIONS COMPRISING LONG ACTING MUSCARINIC ANTAGONISTS - This invention relates to novel pharmaceutical compositions for inhalation comprising separately or together the long acting muscorinic antagonists (LAMAs) in the form of a dry powder in admixture with a pharmaceutically acceptable carrier and its use in the treatment of respiratory condition selected from asthma, chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. | 2015-06-04 |
| 20150150803 | AEROSOL DELIVERY SYSTEMS, COMPOSITIONS AND METHODS - An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol. | 2015-06-04 |
| 20150150804 | CELLULOSE POWDER - This cellulose powder has: an average degree of polymerization of 100 to 350; a weight average particle size of over 30 μm, but less than 250 gm; an apparent specific volume of 2 to less than 15 cm | 2015-06-04 |
| 20150150805 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 2015-06-04 |
| 20150150806 | METHOD FOR PRODUCING MATRIX-TYPE PHARMACEUTICAL SOLID PREPARATION - The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a method for producing a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; (b) a sugar and/or a sugar alcohol, and (c) tolvaptan. | 2015-06-04 |
| 20150150807 | Sol-Gel Phase-Reversible Hydrogel Templates and Uses Thereof - Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template. The method of preparing microstructures based on hydrogel templates is simple and can easily produce large quantities of the microstructures. | 2015-06-04 |
| 20150150809 | Immediate Release Compositions and Methods For Delivering Drug Formulations Using Weak Acid Ion Exchange Resins In Abnormally High pH Environments - Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drugs in abnormally high pH environments wherein the extended release layer is formed from a drug resinate of a strong acid ion-exchange resin and a release rate retarding polymer compressed together. | 2015-06-04 |
| 20150150810 | TABLETS FOR COMBINATION THERAPY - The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV. | 2015-06-04 |
| 20150150811 | TABLET FORMULATION COMPRISING A PEPTIDE AND A DELIVERY AGENT - The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof. | 2015-06-04 |
| 20150150812 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY - The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual. | 2015-06-04 |
| 20150150813 | TABLET MANUFACTURING METHOD AND A TABLET - The object of the present invention is to provide a tablet manufacturing method and also to provide a tablet such as a carbonated spring bathing liquid in which although an aqueous solution after dissolution of the tablet becomes neutral in pH, neutralization reactions are allowed to take place efficiently and intensively inside the tablet, bubbles of carbon dioxide gas which are small in size as much as possible are continuously generated for a certain period of time, thereby the thus generated carbon dioxide gas is mostly dissolved in water without escaping into the air to increase concentrations of total carbonate components in water, and carbon dioxide gas in contact with the skin is designed to be easily converted to bicarbonate ions due to a pH value of the aqueous solution thereof and, therefore, absorbed through the skin, and this subject is solved by a tablet manufacturing method for conducting compression molding in the presence of an organic acid in a range of 1:10 to 1:3 and polyethylene glycol in a range of 1:100 to 1:5 in relation to bicarbonate (sodium hydrogen carbonate or potassium hydrogen carbonate), in which the tablet is subjected to compression molding so that an aqueous solution after dissolution of the tablet is from 5.5 to 8.5 in pH and the tablet is 15 kg or more in hardness and the tablet is also 7 mm or more both in diameter and thickness. | 2015-06-04 |
| 20150150814 | STABLE ORAL PHARMACEUTICAL COMPOSITION OF SOLIFENACIN - The present invention relates to stable oral pharmaceutical compositions comprising solifenacin or a salt thereof prepared by a double compaction process, wherein the amorphous content of solifenacin or a salt thereof in the composition is not less than 80% by weight. It further relates to a method of treating or preventing overactive bladder syndrome by administering said pharmaceutical compositions. | 2015-06-04 |
| 20150150815 | Preparation Method Of The Solid Formulation Of Clopidogrel Bisulfate - A solid formulation of clopidogrel bisulfate and its preparation method are disclosed. The formulation includes clopidogrel bisulfate as active ingredient, colloidal silicon dioxide as anti-adherent/coating and the carriers selected from diluent, binder, glidant, disintegrant and/or lubricant. | 2015-06-04 |
| 20150150817 | FILM COMPOSITION FOR HARD CAPSULE SHELLS - A film-forming composition comprising (a) a cellulose derivative such as HPMC and (b) a urea additive selected from urea, urea derivatives and mixtures thereof; the use of the film-forming composition as a shell material for hard capsules; and films and hard capsules prepared from the film-forming composition. | 2015-06-04 |
| 20150150818 | METHOD AND COMPOSITION OF GLYCOSAMINOGLYCANS IN SICKLE CELL AND VASCULAR DISORDERS - A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof. | 2015-06-04 |
| 20150150820 | PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN - The present invention is directed to a composition comprising particles of pimobendan with an integral coating of a carrier matrix which serve to ensure a rapid dissolution of the active substance at each pH condition representing the gastrointestinal tract and therefore a reliable absorption, and a method of pimobendan microencapsulation using the spray congealing technology and incorporating the coated particles into oral formulations, for example into tablets. | 2015-06-04 |
| 20150150821 | Vault Immunotherapy - The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer. | 2015-06-04 |
| 20150150822 | NOVEL CORE-SHELL NANOPARTICLES FOR ORAL DRUG DELIVERY - The invention relates to an oral nanoparticle drug delivery system, including methods for preparing such a system using a hydrophobic water insoluble protein, which nanoparticles may include prolamine to generate said oral drug delivery system. | 2015-06-04 |
| 20150150823 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 2015-06-04 |
| 20150150824 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 2015-06-04 |
| 20150150825 | METHOD AND SYSTEM FOR FORMING A PHARRMACEUTICAL PRODUCT DIRECTLY ONTO A PACKAGING SURFACE - The present invention relates to a method for forming a pharmaceutical product, such as a dissolvable film dosage form, onto a surface. Particularly, the present invention relates to a method of forming a pharmaceutical product directly onto the surface of a substrate. | 2015-06-04 |
| 20150150826 | ELECTROLYTE IMPREGNATED TIMED-RELEASE STICK-ON PATCH - An adhesive patch applied to a person's skin much like a bandage, comprising an adhesive underside. Affixed to the adhesive underside is a reservoir in contact with the skin, and containing electrolytes and nutrients to be administered transdermally. The reservoir comprises multiple layers. The layer closest to the skin is microporous, thereby permitting substances to migrate from the reservoir to and from the skin. The microporous layer is followed by a pair of layers. The first layer of the pair consists of a water-soluble material, followed by a layer containing electrolytic and nutrient substances to be released. The water-soluble layer dissolves from contact with perspiration, thereby freeing the electrolytic and nutrient substances, allowing them to migrate through the holes to the skin. More pairs of layers may be situated behind such that small amounts of electrolytes are released to the skin over time in a controlled manner. | 2015-06-04 |
| 20150150827 | MULTI-LAYERED TRANSDERMAL SYSTEM WITH TRIAZINE UV ABSORBER - The UV-stable solid transdermal therapeutic system (TTS) with UV absorber for photosensitive active pharmaceutical ingredients has a backing layer ( | 2015-06-04 |
| 20150150828 | Compositions and methods for treating Alzheimer's disease and related disorders and promoting a healthy nervous system - The present invention relates generally to methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. The invention also relates to methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. The invention further provides methods to promote the general health of the nervous system through administration of active ingredient compositions. The invention further relates to animal and cellular systems for the study of AD, MCI, and related disorders, and the identification of reagents useful in treating amyloidosis. The invention further provides methods to inhibit AD or MCI in an individual based on reducing caloric intake by the individual. The invention further relates to a method of treating or inhibiting an amyloidogenic disorder by caloric restriction. | 2015-06-04 |
| 20150150829 | CAPSULES CONTAINING THYMOQUINONE - This invention relates to stable capsule formulations for pharmaceutical, nutraceuticals or food supplements which contain thymoquinone (THQ) as an active ingredient, and which can be stored at room temperature without significant loss of THQ during the shelf life of the capsules. The preferred capsules have a hydroxypropylmethylcellulose (HPMC) shell and may contain carvacrol as an additional active ingredient, either in synthetic form, or as part of a plant extract. Optionally, the capsules may contain a viscosity agent. | 2015-06-04 |
| 20150150830 | HYDROXYBUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS - This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed | 2015-06-04 |
| 20150150831 | SKIN CLEANSING COMPOSITION WITH ENHANCED RHEOLOGICAL PROPERTIES - Materials and apparatus are provided for a skin cleansing composition with enhanced rheological properties. The skin cleansing composition includes a number of surfactants. The skin cleansing composition further includes at least one cationic antimicrobial active. The skin cleansing composition also includes a quaternary amine salt. Ratios of the components of the skin cleansing composition which provide the enhanced rheological properties are also provided. The skin cleansing composition also includes an aqueous medium in which the number of surfactants, the at least one cationic antimicrobial active and the quaternary amine salt are distributed. | 2015-06-04 |
| 20150150832 | METHODS FOR SUPPRESSING CANCER-RELATED CACHEXIA - Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor. | 2015-06-04 |
| 20150150833 | Methods For Treatment of Parkinson's Disease - New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists. | 2015-06-04 |
| 20150150834 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES - The present invention provides a method of inhibiting the growth of or promoting differentiation and destruction of cancer stem cells (CSCs) comprising contacting the cancer stem cells with a compound having the structure: | 2015-06-04 |
| 20150150835 | LACTATE POWDER AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a lactate powder, more particularly a lactate powder having a lactate content of at least 20 wt. % and a water content of less than 3.5 wt. %, said powder comprising calcium cations as well as sodium cations. According to the invention, a calcium lactate powder combining high stability with excellent water dissolution properties can be obtained even though anhydrous calcium lactate represents the bulk of the powder if the powder additionally contains a certain amount of sodium lactate. The inventors have found that the presence of sodium lactate greatly improves the dissolution behavior of the anhydrous calcium lactate while maintaining the storage stability of the powder. The present inventors also established that the dissolution behavior of the powder can be further improved by the addition of a fast-dissolving carbohydrate material. | 2015-06-04 |
| 20150150836 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS - The invention provides methods and compositions for treating dysregulated blood glucose disorders. | 2015-06-04 |
| 20150150837 | COMPOSITION AND METHOD OF TREATMENT OF NASH - The present invention relates to a method of treating NASH or NAFLD by delivery of an effective amount of a composition comprising L-glutamine or butyric acid formulated for release in the colon by bypassing the upper digestive tract and stomach. | 2015-06-04 |
| 20150150838 | ANTIPARASITIC COMPOSITIONS AND METHODS - Compositions and methods for treating parasitic infections are provided. The compositions can include two or more of alpha-pinene, linalyl acetate, para-cymene, and thymol octanoate. The compositions and methods can be effective against, for example, protozoan parasites, helminthic parasites, nematodes, trematodes, flukes, cestodes, and the like. Formulations made from the composition are also provided, including formulations in which the composition is combined with a carrier to form a food product and/or a drink. The formulation can be, for example, a suspension, a solution, or an emulsion in an oily or an aqueous carrier; likewise, the composition can be provided in an encapsulated or microencapsulated form. | 2015-06-04 |
| 20150150839 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE - The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising
| 2015-06-04 |
| 20150150840 | Methods of Treating Hypothalamic Obesity - The invention generally relates to methods of treating a patient suffering from hypothalamic obesity using effective of amounts of a MetAP-2 inhibitor. | 2015-06-04 |
| 20150150841 | Dronedarone for use in Leishmaniasis, Formulations and Associations for Use in Leishmaniasis - The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis. | 2015-06-04 |
| 20150150842 | DESETHYLAMIODARONE COMPOSITIONS - The invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, together with pharmaceutically acceptable excipients, vehicle and/or carrier, as well as the pharmaceutical composition for use in the treatment and prevention of atrial fibrillation with fewer side effects than its parent compound. | 2015-06-04 |
| 20150150843 | CARDIOPROTECTIVE COMPOUNDS, THEIR USE WITH CHEMOTHERAPY, AND METHODS FOR IDENTIFYING THEM - The invention provides a method of reducing anthracycline-induced cardiotoxicity by administering a toxicity-reducing compound, such as a compound of Formulas (I), (II) or (III) or a combination thereof, and/or diphenyl urea (DPU), dexrazoxane (DEX), to a patient receiving an anthracycline. The invention also provides a method of identifying toxicity-reducing compounds. | 2015-06-04 |
| 20150150844 | METHODS AND COMPOSITIONS FOR TREATING CANCER - This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof. | 2015-06-04 |
| 20150150845 | TETRACYCLIC COMPOUND - A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: | 2015-06-04 |
| 20150150846 | V1B RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF PATIENTS HAVING AN ELEVATED AVP LEVEL AND/OR AN ELEVATED COPEPTIN LEVEL - The present invention relates to a vasopressin receptor 1B (V | 2015-06-04 |
| 20150150847 | USE OF N-ACETYL-5-METHOXYTRYPTAMINE OR ANALOGUES THEREOF, FOR PROMOTING THE MECHANISM OF IMPLANTATION OF THE EMBRYO AND RELATED COMPOSITIONS AND CULTURE MEDIA - The present invention refers to the use of N-acetyl-5-methoxytryptamine (melatonin) and/or an analogue thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices. | 2015-06-04 |
| 20150150848 | METHOD FOR OPTIMIZING VISION - A method for optimizing vision by topically administering an ophthalmic formulation in aqueous solution comprising a sterile aqueous carrier including an ophthalmic artificial tear solution, and a pharmaceutically active compound consisting essentially of phentolamine in a therapeutically effective amount to contract a pupil of a human patient's eye in dim light so that the pupil is effectively reduced by 1.0 mm or more to improve vision in dim light and further to minimize eye redness. | 2015-06-04 |
| 20150150849 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS - The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1), wherein R | 2015-06-04 |
| 20150150850 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS - Methods of treating cancer with a compound of formulae (I) or (Ia) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (Ia). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (Ia): | 2015-06-04 |
| 20150150851 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS - Provided is a pharmaceutical composition comprising a pharmaceutically acceptable organic solvent, a pharmaceutically acceptable surfactant, and a compound according to the following formula: wherein the variables are defined herein. Optionally, the pharmaceutical composition further comprises a co-solvent. Also provided is a method of using the pharmaceutical composition disclosed herein for the treatment of a patient in need thereof. | 2015-06-04 |
| 20150150852 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS - Methods and pharmaceutical compositions for treating viral infections, by administering certain 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. | 2015-06-04 |
| 20150150853 | PROMOTING SLEEP USING AT1 RECEPTOR BLOCKERS - The present invention relates to the use of an Angiotensin II type 1 (AT1) receptor blocker for promoting sleep and/or the treatment of insomnia. It is based, at least in part, on the results of experiments performed using a validated rat model of stress-induced insomnia in which candesartan was found to ameliorate sleep disturbances induced by stress. Further, it was observed that this effect seems to be caused by blockade of AT1 receptors located in several brain regions that are key components of the neural circuitry activated during insomnia. In contrast to currently marketed treatments for insomnia, the AT1 receptor blocker was found to restore normal sleep without inhibiting REM sleep and/or inducing atypical wave components in the EEG. | 2015-06-04 |
| 20150150854 | INJECTABLE ANTIBIOTIC FORMULATIONS AND THEIR METHODS OF USE - This invention relates to a composition, including penethamate (PNT) or a pharmaceutical equivalent thereof; and triacetin. | 2015-06-04 |
| 20150150855 | METHOD OF IMPROVING LIVER FUNCTION - The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient. | 2015-06-04 |
| 20150150856 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: | 2015-06-04 |
| 20150150857 | Methods of Treating an Overweight or Obese Subject - The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including MetAp-2 inhibitory compound, or s salt, ester, or prodrug thereof, effective to result in weight loss in the subject. | 2015-06-04 |
| 20150150858 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER - Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions. | 2015-06-04 |
| 20150150859 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING - A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening. | 2015-06-04 |
| 20150150860 | Small Molecules Modulator of Epigenetic Regulation and Their Therapeutic Applications - Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof | 2015-06-04 |
| 20150150861 | ANTIBACTERIAL COMPOUNDS - Disclosed are compounds of formula (I): | 2015-06-04 |
| 20150150862 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases. | 2015-06-04 |
| 20150150863 | COMPOSITIONS AND METHODS FOR TREATING PELVIC PAIN AND OTHER CONDITIONS - Methods are provided for treating conditions including chronic pelvic pain, in which there are palpable trigger points of local areas of muscle restriction and spasticity that recreate or refer pain of patients complaints upon palpation, chronic pelvic pain syndrome, pelvic floor myalgia, pelvic floor dysfunction, interstitial cystitis, levator ani syndrome, coccygodynia, prostatodynia, piriformis syndrome, anal sphincter pain, bowel movement pain, post bowel movement pain, ejaculatory pain, post ejaculatory pain, sitting pain, post bowel movement pain, rectal pain, tailbone pain, urinary frequency, urinary urgency, urinary hesitancy, post urinary pain, overactive bladder, perineal pain, penile pain, vaginismus, anismus, sexual dysfunction, reduced level of ejaculate or reduced penile erection, myofascial pain in muscle tissue of a patient who has one or more trigger points in the muscle tissue, or the pain/sensitivity of pelvic floor muscle trigger points and specific areas of myofascial restriction detected upon palpation in a patient comprising administering to the one or more trigger points of the patient in need thereof a therapeutically effective amount of a calcium channel blocker, or L-arginine, or a combination of a calcium channel blocker and L-arginine, or pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof; the application of the topical form of the drug can be applied by the patient regularly as part of a self treatment program to heal muscle related pain and muscle related pelvic pain and each optionally together with a corticosteroid such as cortisone of hydrocortisone. The invention further provides methods for myofascial release, trigger point release, and the use of dilators with and without calcium channel blockers for pain conditions. The invention further provides pharmaceutical compositions, kits and applicator devices useful in the methods of the invention. | 2015-06-04 |
| 20150150864 | SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE)BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIBITORS - In one aspect, the invention relates to substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2015-06-04 |
| 20150150865 | COMBINATION DRUG FOR TREATING VASCULAR DISORDER - The present invention relates to a medicament for treating occlusive and/or ischemic vascular disorder comprising a carbostyril derivative and carnitine. | 2015-06-04 |
| 20150150867 | COMPOSITIONS OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)-PHENYL]PIPERAZINE - Pharmaceutical compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof adapted so that release does not take place in the stomach is provided. | 2015-06-04 |
| 20150150868 | ARIPIPRAZOLE-ORGANIC ACID COCRYSTAL, PREPARATION OR COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR - According to the present invention, a formulation or composition containing the same, and a preparation method thereof, a novel cocrystal free of hygroscopicity can be obtained by adding an organic acid such as salicylic acid to an anhydrous aripiprazole crystal. In addition, an industrially useful grinding process is provided, which enables the convenience of preparation of the cocrystal and worker's safety to be ensured and allows the preparation of the cocrystal to be performed without needing a special chemical system. | 2015-06-04 |
| 20150150869 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES - The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 2015-06-04 |
| 20150150870 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS - This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-x | 2015-06-04 |
| 20150150871 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS - The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. | 2015-06-04 |
| 20150150872 | INHIBITORS OF BETA-SECRETASE - The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. | 2015-06-04 |
| 20150150873 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS - The present invention provides a compound of formula (A): | 2015-06-04 |
| 20150150874 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2015-06-04 |
| 20150150875 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS - The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels. | 2015-06-04 |
| 20150150876 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS - The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. | 2015-06-04 |
| 20150150877 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, | 2015-06-04 |
| 20150150878 | Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins - The disclosure provides methods and compositions useful for inhibiting virus requiring membrane fusion for viral entry, specifically for inhibiting severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), Hendra (HeV) and Nipah (NIV) viruses by targeting Cathepsin-L (CatL) cleavages sites in the viruses' glycoproteins. | 2015-06-04 |
| 20150150879 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases - The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions. | 2015-06-04 |
| 20150150880 | Hypotensive Lipid And Timolol Compositions And Methods Of Using Same - New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension. | 2015-06-04 |
| 20150150881 | METHODS FOR TREATING CANCERS - Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: | 2015-06-04 |
| 20150150882 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 2015-06-04 |
| 20150150883 | CEFTOLOZANE-TAZOBACTAM PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam. | 2015-06-04 |
| 20150150884 | BROMODOMAIN INHIBITORS - The present invention provides for compounds of formula (I) | 2015-06-04 |
| 20150150885 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders - The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail). | 2015-06-04 |
| 20150150886 | COMPOSITIONS, METHODS AND KITS FOR TREATING CANCER - Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ | 2015-06-04 |
